Striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory and other debilitating diseases.
OUR RESEARCH
Our current pipeline aims to disrupt existing treatment paradigms and features new molecular entities with first-in-class potential as treatments for autoimmune, inflammatory, and other high unmet need conditions.
Unlike existing broad immunosuppressants for treatment of autoimmune disease, DYRK1A inhibition may restore immune homeostasis, which represents a paradigm shift in the treatment of autoimmune and inflammatory diseases.
LEARN MORE
DYRK1A in Autoimmunity
A dysregulated type I interferon response may underlie broader autoimmune and inflammatory diseases, for which STING inhibition presents a novel, targeted therapeutic approach.
LEARN MORE
STING in Inflammation
Brickell’s novel platform of next-generation kinase inhibitors includes blood-brain barrier penetrating compounds, making them prime candidates to convert a promising target into viable treatment options for patients with neuroinflammatory diseases.
LEARN MORE
Neuroinflammation
VIEW OUR PIPELINE